F M Investments LLC Sells 16,278 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

F M Investments LLC reduced its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 19.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,401 shares of the medical instruments supplier’s stock after selling 16,278 shares during the period. F M Investments LLC owned approximately 0.28% of ICU Medical worth $12,646,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC increased its position in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares during the period. Allworth Financial LP increased its position in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the period. Innealta Capital LLC bought a new stake in shares of ICU Medical during the second quarter valued at approximately $32,000. Motco bought a new stake in shares of ICU Medical during the first quarter valued at approximately $29,000. Finally, EntryPoint Capital LLC increased its position in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the period. 96.10% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,552 shares of company stock valued at $6,679,322 over the last 90 days. 6.70% of the stock is owned by company insiders.

ICU Medical Price Performance

ICU Medical stock traded up $0.09 on Friday, reaching $170.82. The company’s stock had a trading volume of 271,355 shares, compared to its average volume of 274,570. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The company has a market cap of $4.17 billion, a price-to-earnings ratio of -58.50 and a beta of 0.66. The business’s fifty day moving average price is $174.09 and its 200 day moving average price is $137.21. ICU Medical, Inc. has a twelve month low of $78.28 and a twelve month high of $188.53.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. Equities analysts expect that ICU Medical, Inc. will post 3.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ICUI. Raymond James boosted their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group initiated coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. KeyCorp boosted their price target on ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $170.25.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.